A vehicle starts to move from the rest gets an acceleration of 5 m/s2 within 2 seconds. Calculate the velocity and distance covered by the vehicle within the given time

plz help me

For problems 1-3, consider a simple dc brush motor with a permanent magnet stator. with an an consider a simple dc brush motor with a permanent magnet ae supply voltage of 100 v, the no-load speed of the motor is 1000 rpm. this motor can provide a torque of 1.9 n-m at 800 rpm drawing a current of 2 a current are both zero at no load.) 1. with an armature supply voltage of 100 v, the motor is operated at 900 rpm. what is the motor torque? what is the mechanical power delivered by the motor? what is the current draw? what is the electrical power input? what is the energy efficiency of the motor? with an armature supply voltage of 100 v, the motor is operated at 1100 rpm (where it acts as a generator). what torque input is required? what mechanical power is required what current is generated? what is the electrical power generated? what is the energy efficiency of the motor acting as a generator? 2. with an armature supply voltage raised to 120 v, the motor is operated at 1000 rpm. what is the no-load speed? what is the motor torque? what is the mechanical power delivered by the motor? what is the current draw? what is the electrical power input what is the energy efficiency of the motor? 3.

Which car has the most kinetic energy? a. a car of mass 1000 kg with a speed of 3 m/s b. a car of mass 2000 kg with speed 7 m/s c. a car of mass 1000 kg with speed 7 m/s d. a car of mass 2000 kg with speed 3 m/s

Asubject in a clinical research trial experiences a serious, unanticipated adverse drug experience. how should the investigator proceed, with respect to the irb, after the discovery of the adverse event occurrence? a. do not report the adverse drug experience to the irb since it is a common adverse experience.b. report the adverse drug experience to the irb only if there are several other occurrences.c. report the adverse drug experience as part of the continuing review report.d. report the adverse drug experience in a timely manner, in keeping with the irb's policies and procedures, using the forms or the mechanism provided by the irb.